The estimated Net Worth of Glenna Mileson is at least $503 Thousand dollars as of 28 December 2022. Ms Mileson owns over 50,000 units of Athira Pharma stock worth over $78,366 and over the last 4 years she sold ATHA stock worth over $7,032. In addition, she makes $417,645 as Chief Financial Officer at Athira Pharma.
Sign up
Ms Mileson ATHA stock SEC Form 4 insiders trading
Ms has made over 5 trades of the Athira Pharma stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 50,000 units of ATHA stock worth $142,500 on 28 December 2022.
The largest trade she's ever made was buying 50,000 units of Athira Pharma stock on 28 December 2022 worth over $142,500. On average, Ms trades about 8,528 units every 74 days since 2021. As of 28 December 2022 she still owns at least 159,930 units of Athira Pharma stock.
You can see the complete history of Ms Mileson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Glenna K. Mileson biography
Glenna K. Mileson is the Chief Financial Officer at Athira Pharma.
What is the salary of Ms Mileson?
As the Chief Financial Officer of Athira Pharma, the total compensation of Ms Mileson at Athira Pharma is $417,645. There are 1 executives at Athira Pharma getting paid more, with Dr. Hans Moebius having the highest compensation of $425,058.
How old is Ms Mileson?
Ms Mileson is 62, she's been the Chief Financial Officer of Athira Pharma since . There are 1 older and 2 younger executives at Athira Pharma. The oldest executive at Athira Pharma, Inc. is Dr. Hans Moebius, 64, who is the Chief Medical Officer.
What's Ms Mileson's mailing address?
Glenna's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Insiders trading at Athira Pharma
Over the last 4 years, insiders at Athira Pharma have traded over $100,296 worth of Athira Pharma stock and bought 5,411,219 units worth $62,123,025 . The most active insiders traders include Advisors Llcperceptive Life..., Investments, Lpwong Roderic..., and Joseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of $62,547. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth $725.
What does Athira Pharma do?
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
What does Athira Pharma's logo look like?
Complete history of Ms Mileson stock trades at Athira Pharma
Athira Pharma executives and stock owners
Athira Pharma executives and other stock owners filed with the SEC include:
-
Dr. Hans Moebius,
Chief Medical Officer -
Glenna K. Mileson,
Chief Financial Officer -
Dr. Kevin Church Ph.D.,
Exec. VP of Research -
Mark F. Worthington J.D.,
Gen. Counsel & Corp. Sec. -
Julie Rathbun,
Head of Investor Relations -
Robert Renninger,
Director of Accounting & Reporting -
Rachel P. Lenington M.B.A.,
Chief Operating Officer -
Dr. Mark J. Litton M.B.A., MBA, Ph.D.,
Pres, CEO & Director -
James A Johnson,
-
Kelly A Romano,
-
Rachel Lenington,
COO and CDO -
Michael A. Panzara,
-
Kevin Church,
CHIEF SCIENTIFIC OFFICER -
Advisors Llcperceptive Life...,
-
Investments, Lpwong Roderic...,
-
Martin Javier San,
CHIEF MEDICAL OFFICER -
John M Jr Fluke,
-
Advisors Llcperceptive Life...,
-
Barbara Kosacz,
-
Leen Kawas,
President & CEO -
Hans Moebius,
Chief Medical Officer -
Glenna Mileson,
Chief Financial Officer -
Tadataka Yamada,
Director -
Mark Worthington,
GENERAL COUNSEL -
Joseph Edelman,
-
Grant Pickering,
-
Mark James Litton,
President and CEO